

УКРАЇНА

UKRAINE



ПАТЕНТ

ON UTILITY MODEL  
НА КОРИСНУ МОДЕЛЬ

№ 22012

A remedy "FLARAXIN" to treat viral diseases and cancer diseases  
ЗАСІБ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ТА ОНКОЛОГІЧНИХ  
ЗАХВОРЮВАНЬ "ФЛАРАКСИН"

Issued according to law of Ukraine "On Protection of Rights to Inventions and Utility Models"  
Видано відповідно до Закону України "Про охорону прав на винаходи і корисні моделі".


Registered in the State Register of Patents of Ukraine for utility models 10 April 2007.  
Зареєстровано в Державному реєстрі патентів України на корисні моделі 10 квітня 2007 р.

Head of the State Department of Intellectual Property  
Голова Державного департаменту  
інтелектуальної власності

M.V. Paladiy  
М.В. Паладій



Ministry of Education and Science of Ukraine  
State Department of Intellectual Property



## ЗАСІБ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ТА ОНКОЛОГІЧНИХ ЗАХВОРЮВАНЬ "ФЛАРАКСИН"

Бібліографічні дані	Реферат (uk)	Реферат (ru)	Реферат (en)	Опис
Патент на корисну модель				патент діє 
(11) 22012	(51) МПК (2006) A61K 36/00			
(24) 10.04.2007				
(21) u200611815	(22) 10.11.2006			
(46) 10.04.2007, бюл. № 4				
(71) КОЛИЧЕВ МИХАЙЛО ОЛЕКСАНДРОВИЧ (UA); БОГДАН МИКОЛА АНДРІЙОВИЧ (UA); МАКСИМЕНКО ГЕОРГІЙ ІВАНОВИЧ (UA)				
КОЛЬЧЕВ МИХАЙЛ АЛЕКСАНДРОВИЧ (UA); БОГДАН НИКОЛАЙ АНДРЕЕВИЧ (UA); МАКСИМЕНКО ГЕОРГІЙ ІВАНОВИЧ (UA)				
KOLYSCHEV MYKHAILO OLEKSANDROVYCH (UA); BOHDAN MYKOLA ANDRIIOVYCH (UA); MAKSYMENKO HEORHIY IVANOVYCH (UA)				
(72) Количев Михайло Олександрович (UA); Богдан Микола Андрійович (UA); Максименко Георгій Іванович (UA)				
Кольчев Михаил Александрович (UA); Богдан Николай Андреевич (UA); Максименко Георгий Иванович (UA)				
Kolychev Mykhailo Oleksandrovych (UA); Bohdan Mykola Andriiovych (UA); Maksymenko Heorhii Ivanovych (UA)				
(73) КОЛИЧЕВ МИХАЙЛО ОЛЕКСАНДРОВИЧ, вул.Світла, 8, кв.33, м.Харків, 61213 (UA); БОГДАН МИКОЛА АНДРІЙОВИЧ, вул.Котлова, 250/5, кв.10, м.Харків, 61139 (UA); МАКСИМЕНКО ГЕОРГІЙ ІВАНОВИЧ, пр.Людвіка Свободи, 35-б, кв.12, м.Харків, 61202 (UA)				
КОЛЬЧЕВ МИХАЙЛ АЛЕКСАНДРОВИЧ (UA); БОГДАН НИКОЛАЙ АНДРЕЕВИЧ (UA); МАКСИМЕНКО ГЕОРГІЙ ІВАНОВИЧ (UA)				
KOLYSCHEV MYKHAILO OLEKSANDROVYCH (UA); BOHDAN MYKOLA ANDRIIOVYCH (UA); MAKSYMENKO HEORHIY IVANOVYCH (UA)				
(98) Максименко Георгій Іванович пр. Людвіка Свободи, 35-б, кв. 12, м.Харків, 61202, Україна (UA)				
(54) ЗАСІБ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ТА ОНКОЛОГІЧНИХ ЗАХВОРЮВАНЬ "ФЛАРАКСИН"				
FLARAXIN, COMPOSITION FOR TREATING VIRAL AND ONCOLOGICAL DISEASES				
СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ И ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ "ФЛАРАКСИН"				
(57)				<a href="#">ВІДКРИТИ У НОВОМУ ВІКНІ</a>
Засіб для лікування вірусних і онкологічних захворювань на основі таніну і йодиду калію, який відрізняється тим, що він виконаний у вигляді кластера, який складається з молекул таніну і йодиду калію.				

## DESCRIPTION OF THE PATENT № 22012

The proposed remedy relates to medicine and veterinary medicine and can be used to treat viral diseases and cancer. Known medicines based on plant flavonoids (FITOR; FITOMAX) that can be used in the treatment of viral diseases. The medicinal properties of these drugs related to their ability to induct interferon in the body [V. Rossikhin, I.A.Egorov, A.G.Bazarynsky, N.I.Reutsky "Prostate and adenoma of prostate gland", Kharkov, 2004].

As proposed utility model, known products contain vegetable flavonoids. Obstacles to obtaining the technical effect is the absence of known drugs antioxidant activity and their inability to bind conformationally altered proteins (cancer cells). Tannin is a commonly known in pharmacology [M.D.Mashkovskiy "Pharmaceutical remedies", part 1, Moscow, 1988, p.377] - plant flavonoid that has antioxidant activity and can bind to conformationally altered proteins, but until recently the use of tannin for intravenous administration was considered impossible. The main obstacle to the use of tannin for injection is its tanning properties. When you inject tannin in the blood vessel than a flash-binding proteins will take place in the blood and will be produced a mortally dangerous blood clots for the body.

As a prototype selected patent 25833 "The remedy for the melanoblastoma treatment" patented in Ukraine, clinical trial A61K35 / 78, 1999. The known product contains tannin and potassium iodide and is intended for intravenous injection in the body. This remedy refers to low-toxic combinations with high antitumor activity.

Previous application of this remedy on melanoblastoma showed that it acts separately on organs that damaged by tumors and makes minimal irritation in the body and do not affect on the general condition of the patient.

As proposed utility model, a prototype containing tannin and potassium iodide. Obstacles to obtaining the technical result is that the drug contains a mechanical mixture of tannin and potassium iodide, and the uncertainty of product characteristics is due to uncertainty in characteristics of tannin, which is part of the preparation. Tannin is not an individual substance, its composition not a certain specific formula, its properties (in a first case its activity) vary

depending on various factors, such as tannin nature, character of storage and production. During production of medication on the following principles there is a significant chance that the drug will contain excess of tannin or potassium iodide.

Intravenous administration of the drug in the first case, the body may produce deadly dangerous blood clots in the second case - worsening the work of heart muscle.

The target, which should be solved by the utility model is to create a means the remedy to treat viral diseases and cancer, which are not inherent properties of previous negative analogs.

The technical result that can be obtained during application of remedy is the ability to establish an optimal cluster ratio of tannin and potassium iodine, which creates conditions for selective action on tumors without damage of healthy organs and systems. This is achieved by creating opportunities for identification of tannin and regulation of its surface activity.

The essence of the invention is that the remedy for treatment of viral diseases and cancer, based on tannin and potassium iodide, made as a cluster that is made up of molecules of tannin and potassium iodide. The proposed utility model differs from the prototype by cluster structure that is made up of molecules of tannin and potassium iodide.

Between the essential features of the proposed invention and technical result that can be achieved during its application exists other causal results.

By various spectral methods, it was found that the interaction of tannin and potassium iodine were an absorption of potassium iodide by the tannin molecules, which leads to the formation of molecules with new properties (abilities), in the first case changes in the surface activity of tannin molecules. The substance consisting of such molecules are not able to actively stimulate the denaturation of blood proteins. Only some molecules of proteins with increased activity, which caused by conformational changes are able to interact with molecules of tannin saturated by molecules of potassium iodide. The existence of the absorption mechanism allows the identification of different types of tannin and received substance is a cluster-system with a large number of weakly connected atoms or molecules. [Physical Encyclopedia, the editor A.M.Prokhorova, Moscow, "Soviet Encyclopedia", 1990].

The proposed remedy is prepared as follows. In a solution that contains a certain amount of tannin added a solution of potassium iodide until the full saturation. Achieving saturation determined by color changes with the addition of 5% alcoholic solution of iodine.

#### **Example 1**

To 5 parts of a 10% solution of tannin should be added 1 part of a solution of potassium iodide. In the solution is administered 5% alcoholic iodine solution by drops till the moment of color changes. The color had changes after addition of 20 drops of iodine solution.

The remedy cannot be used for intravenous administration with regard to the fact that substance shows properties of tannin and is not a cluster. The injection of such product intravenously in blood vessels can lead to blood clots production. It's dangerous.

#### **Example 2**

Up to 4 parts of a 10% solution of tannin should be added 1 part of potassium iodide. In the solution is administered 5% alcohol solution of iodine by drops till the moment of color changes. Color began to have changes into red after administration of two drops of iodine solution.

The remedy can be used for intravenous administration, due to the fact that it reveals properties of cluster.

#### **Example 3**

To 2 parts of 10% solution of tannin should be added 1 part of a solution of potassium iodide. In the solution in administered 5% alcoholic solution of iodine by drops till the moment of color changes. The first two drops of iodine solution give color changes to brown in the solution, indicating the excess of potassium iodide inside.

The remedy cannot be used for intravenous administration due to the fact that it is not a cluster, Injection of such remedy into the blood vessels will impairs the work of heart muscle.

Experimental study of the drug properties have been performed by medical scientists that have proved high efficacy of drug, which is a cluster consists of tannin and potassium iodine.

For example, high antioxidant activity of the drug was confirmed in the "Assessment of antioxidant activity of Flaraxin on early stages free-radical oxidation" A.V.Artemov, V.V.Rossikhin. The second international periodic scientific-practical conference "Alliance of sciences: from scientist to scientist", 3-7 October, 2005.. Festschrift of Scientific Work, Volume 3, page16, Dnepropetrovsk, 2005.

In the book "New Method of treatment for oncologic, immune dependent and viral diseases" Publishing House of Medical Center "Mercury", Odessa, 2004, page81 were confirmed drug activity of FLARAKSYN during interaction with conformationally altered proteins.

In the "Festschrift of Scientific Papers of Ukrainian Military Medical Academy", issue3, KIEV-2000 edited by prof.V.J.Beliy in the article "The influence of cytostatics SH-SS groups of blood serum on oncological processes", authors S.L.Dohnuv, V.G.Vasylyuk and others, page 79, confirmed; Flaraxin efficiency in the treatment of cancer diseases.

In the book of "Non-toxic medicinal therapy of cancer: physiopathology mechanisms and clinical features" Publishing House "Rayder ". Kharkov, 2002, confirmed the high efficiency of the cancer treatment by Flaraxin.